A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Status:
Not yet recruiting
Trial end date:
2023-02-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into
the bloodstream and how long it takes the body to eliminate it in female participants with
impaired liver function compared to female participants with normal liver function. The side
effects and tolerability of Imlunestrant will also be evaluated. The study may last up to 46
days for each participant.